This is a slow-growing form of B-cell lymphoma. About 20% to 30% of all non-Hodgkin's lymphomas are follicular lymphoma (FL). This cancer usually starts in people who are over 65. It usually grows ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan: Tokyo Thursday, March 20, 2025, 11:00 Hrs ...

follicular lymphoma (FL) after 2 or more lines of systemic therapy. Odronextamab is an investigational bispecific antibody that binds to CD20 expressed on the surface of B cells, and to CD3 ...